Bronchodilators Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Bronchodilators Market is segmented by Drug Type (Beta-Adrenergic Bronchodilators, Xanthine Derivatives, and Anticholinergic Bronchodilators), Route of Administration (Oral, Injectable, and Nasal), Indication (Asthma, Chronic Obstructive Pulmonary Disease, and Other Indications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Study Period: 2018-2026
Base Year: 2020
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 4.7 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The bronchodilators market studied is expected to grow with an estimated CAGR of 4.7%, over the forecast period.

Substantial increase in the number of patients with respiratory disorders on an account of COVID-19 are projected to trigger the demand for bronchodilators across the globe. Several research studies suggest that the use of bronchodilator medications in treating COVID-19 patients can facilitate normal breathing and functional improvements. These medications are mainly useful in confirmed or suspected COVID-19 cases with reactive airway diseases. A June 2021 study published in Respiratory Medicine Journal, aimed at confirming the level of bronchodilator reversibility in SARS‑CoV‑2 patients undertaking multidisciplinary pulmonary rehabilitation after the acute phase. The study concluded that the use of bronchodilators should be considered in post-COVID-19 patients as it can encourage functional improvements in the lungs for normal breathing. However, some research studies contrast the usefulness of bronchodilators and conclude that no significant changes are observed in affected patients with minimal improvement in clinical outcomes for reducing the risk of mortality. For instance, recently, in 2021, a retrospective cohort study was carried to evaluate the association between the length of COVID-19 pneumonia patient stay in the hospitals and the use of inhaled bronchodilators in Spain. The results concluded from the study did not specify any notable health improvements among patients. As a result, the bronchodilators market is anticipated to be moderately impacted by the pandemic.

The studied market growth can be attributed to a variety of factors, such as the rising prevalence of respiratory diseases globally coupled with increased levels of air pollution, the surge in the number of smokers, and propelling incidence of infectious diseases among the elderly population significantly contributing toward the risk of developing lung disorders, and are collectively driving the market growth.

One of the key parameters responsible for the growth of the bronchodilators market is the gradual decrease in functionality of lungs along with the age of an individual. Thus, these cognitive and physical changes usually make normal breathing difficult in the elderly, thereby, driving the growth of the market. The geriatric population is more vulnerable to respiratory disorders such as chronic obstructive pulmonary disease (COPD) and asthma. For instance, as per the data published by the Centers for Disease Control and Prevention (CDC), in 2019, around 4,069,278 Americans aged above 65 years were living with asthma. Since bronchodilators play a vital role in maintaining optimal airflow within the lungs of these patients, this is likely to boost the demand for bronchodilators in near future. Additionally, a rising number of product launches and approvals are expected to have a positive impact on the demand for bronchodilators within the patient population. For instance, in July 2020, EVA Pharma launched ‘Inhalex’, the first Egyptian medication for COPD with a 24-hour lasting effect. This product launch is projected to reduce the cost of the treatment of COPD patients to half. On the contrary, possible side effects such as tremors, coughs, increased heart rate, and nervousness are likely to obstruct the market growth over the forecast period.

Scope of the Report

As per the scope of the report, a bronchodilator is a type of medication used in relaxing the muscles present in the airway passages of the lungs (bronchi) and widening them for easier breathing. They decrease the resistance in the respiratory passage and increase the airflow within the lungs. The Bronchodilators Market is segmented by Drug Type (Beta-Adrenergic Bronchodilators, Xanthine Derivatives, and Anticholinergic Bronchodilators), Route of Administration (Oral, Injectable, and Nasal), Indication (Asthma, Chronic Obstructive Pulmonary Disease, and Other Indications), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Drug Type
Beta-Adrenergic Bronchodilators
Xanthine Derivatives
Anticholinergic Bronchodilators
By Route of Administration
By Indication
Chronic Obstructive Pulmonary Disease
Other Indications
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle East and Africa
South Africa
Rest of Middle East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Asthma Segment is Expected to Register a Substantial Growth in the Bronchodilators Market

Based on indication, the asthma segment is estimated to garner significant growth throughout the forecast period. This is majorly attributed to the rising prevalence of asthma worldwide. For instance, as per World Health Organization (WHO) data, asthma affected around 262 million people in 2019 and triggered 461,000 deaths worldwide. Asthma is a breathing disorder caused due to narrowing of airway passages within the lungs. The narrowing may occur due to numerous reasons such as muscle spasms, excess production of mucus, or swelling in the airway. Amidst an asthma attack, the muscles in the airway begin to tighten, leading to narrowing of airways. Moreover, the lining of these passages tends to swell and results in the overproduction of mucus. This causes difficulty in breathing. Bronchodilators relieve these symptoms of asthma by opening the airways and counteract the effects of an attack. In addition, the surge in product approval and launches for treating asthma is further estimated to supplement the segment growth. For instance, in May 2019, Sanofi received a European Commission approval for its ‘Dupixent’ used in treating patients with severe asthma. Furthermore, United States Food and Drug Administration (USFDA) accepted ‘Dupixent’ for review in March 2021. Thus, the increasing number of pipeline products along with an upsurge in asthma-affected population and ease of availability of bronchodilator medications are expected to propel the growth of the bronchodilators market in the years to come.


North America is Expected to Hold a Major Share of the Market throughout the Forecast Period

Within North America, the United States has held the major share of the market and is expected to dominate over the forecast period. Chronic Obstructive Pulmonary Disease (COPD) affects millions of Americans each year and is the third foremost cause of disease-associated death in the United States. For instance, according to the data published by American Lung Association, in 2018, approximately 16.4 million adults in the United States reported a diagnosis of any type of COPD (emphysema, chronic bronchitis, or COPD). Likewise, asthma continues to be a serious public concern within the country. The United States Environmental Protection Agency and the National Health Interview Surveys (NHIS), in April 2021, estimated that almost 25.1 million people, comprising 5.1 million children, have asthma in the country. The same source also stated that, in 2019, over 10.3 million people with asthma, with nearly 2.3 million children, report having had one or more asthma attacks. Since bronchodilators are usually recommended as the first‐line of treatment for respiratory-related disorders, the North American region is anticipated to be the major revenue contributor throughout the analysis period. In addition, an upsurge in the number of smokers in the region along with a tremendous increase in environmental pollution are some of the other factors propelling the market growth for bronchodilators. Likewise, continuous R&D efforts of the regional market players for developing an efficacious treatment for patients with respiratory disorders is projected to impel the market growth. For instance, Regeneron Pharmaceuticals, Inc., an American biotechnology company collaborated with Sanofi for studying pediatric asthma. The drug candidate is currently in its Phase III clinical study and is estimated to be completed by September 2021. 

Thus, these aformentioned factors collectively are responsible for driving the growth of bronchodilators market in North America.


Competitive Landscape

The bronchodilators market is highly competitive with several key players across the globe. In terms of market share, various major players currently dominate the market. With the rising patient awareness levels and high prevalence of respiratory diseases, many regional players are expected to be part of the bronchodilators market over the forecast period. Some of the major players of the market are Teva Pharmaceutical Industries Ltd., Novartis AG, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Cipla Inc., and AstraZeneca among others.

Recent Developments

In May 2020, Glenmark Pharmaceuticals Ltd. Successfully launched Single Inhaler Triple Therapy (AIRZ-FF) which is a combination of two bronchodilators, namely, Formoterol and Glycopyrronium, and corticosteroid Fluticasone propionate, for Chronic Obstructive Pulmonary Disease (COPD) patients in India.

In October 2020, Zydus Cadila received final approval from the United States Food and Drug Administration (USFDA) to market Albuterol Tablets (in the strengths of 2 mg and 4 mg) used in treating and preventing bronchospasm.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Surge in Patient Population with Respiratory Disorders

      2. 4.2.2 Significant Rise in Environmental Pollution

      3. 4.2.3 Increasing Number of Smokers

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects of Bronchodilators

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Drug Type

      1. 5.1.1 Beta-Adrenergic Bronchodilators

      2. 5.1.2 Xanthine Derivatives

      3. 5.1.3 Anticholinergic Bronchodilators

    2. 5.2 By Route of Administration

      1. 5.2.1 Oral

      2. 5.2.2 Injectable

      3. 5.2.3 Nasal

    3. 5.3 By Indication

      1. 5.3.1 Asthma

      2. 5.3.2 Chronic Obstructive Pulmonary Disease

      3. 5.3.3 Other Indications

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca

      2. 6.1.2 Boehringer Ingelheim International GmbH

      3. 6.1.3 Cipla Inc.

      4. 6.1.4 GlaxoSmithKline plc

      5. 6.1.5 Harman Finochem Ltd

      6. 6.1.6 Innoviva

      7. 6.1.7 Novartis AG

      8. 6.1.8 Sanofi

      9. 6.1.9 Sunovion Pharmaceuticals

      10. 6.1.10 Teva Pharmaceutical Industries Ltd

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products, Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Bronchodilators Market market is studied from 2018 - 2026.

The Global Bronchodilators Market is growing at a CAGR of 4.7% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

AstraZeneca, Teva Pharmaceutical Industries Ltd., Novartis AG, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc are the major companies operating in Global Bronchodilators Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!